Status:
COMPLETED
Immune Profiling in Multiple Myeloma
Lead Sponsor:
Mario Boccadoro
Conditions:
Multiple Myeloma
Eligibility:
All Genders
Brief Summary
This study propose to investigate the immune repertoire of MM patients at the time of diagnosis vs. 1st vs. 2nd vs. 3rd relapse. This study will provide insights into the immune status of MM patients ...
Detailed Description
Background: Immunotherapy has emerged as a new therapeutic strategy for the treatment of multiple myeloma (MM). The current immune-based strategies include the FDA-approved monoclonal antibodies elotu...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- newly diagnosed MM patients or
- refractory MM patients or
- healthy donors.
- Esclusion criteria:
- not newly diagnosed MM patients or
- not refractory MM patients or
- no healthy donors.
Exclusion
Key Trial Info
Start Date :
April 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 16 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04135079
Start Date
April 15 2019
End Date
December 16 2024
Last Update
January 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aou Citta' Della Salute E Della Scienza Di Torino
Torino, TO, Italy, 10126